Home » Topics » BioWorld Science

BioWorld Science
RSS

Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis

July 27, 2021

Cerecor reports initial phase Ib data on CERC-002 in moderate to severe Crohn's disease

July 27, 2021

Jiangsu Simcere Pharmaceutical R&D describes TGF-beta receptor type-1 inhibitors

July 27, 2021

Ophirex initiates phase II study of varespladib in severe COVID-19

July 27, 2021

New DGAT-2 inhibitors discovered at LG Chem

July 27, 2021

Beijing Scitech-Mq Pharmaceuticals identifies new FGFR4 inhibitors

July 27, 2021

Japan Tobacco divulges new NLRP3 inflammasome inhibitors

July 27, 2021

Yeast study reveals potential cancer therapy approach

July 27, 2021

PolarityTE submits IND for SkinTE in chronic cutaneous ulcers

July 27, 2021

Interim update on first-in-human study of SB-11285 in solid tumors

July 27, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...